Dr. Lal PathLabs informs about outcome of committee meet

18 Mar 2024 Evaluate

Dr. Lal PathLabs has informed that, based on recommendations of Nomination & Remuneration Committee, the Board of Directors in their meeting held on March 17, 2024, approved the re-designation of Shankha Banerjee by appointing him as Chief Executive Officer (CEO) and Key Managerial Personnel (KMP) with effect from May 21, 2024. The disclosure as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 and other applicable circulars, if any, is enclosed as ‘Annexure A’. Further, in view of above appointment and pursuant to Regulation 30(5) of Listing Regulations, the company has enclosed the details of the authorized persons for the purpose of determining materiality of any event or information, which shall be effective from May 21, 2024. Based on the decision of the above-named officials, the Compliance Officer shall be responsible for making disclosure to the Stock Exchange(s) and his contact details are also enclosed. The Board Meeting commenced at 11:00 am (IST) and concluded at 11:18 am (IST).

The above information is a part of company’s filings submitted to BSE.



Dr. Lal Pathlabs Share Price

2465.75 -25.45 (-1.02%)
15-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Aster DM Healthcare 350.30
Apollo Hospital Ent. 5857.70
Max Healthcare Inst 830.70
Narayana Hrudayalay 1255.00
Global Health 1409.80
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.